The incidence of thyroid cancer has been increasing,and early diagnosis and treatment are crucial for improving patient prognosis.With the advancement of artificial intelligence(AI)technology,significant progress has been made in its application in the diagnosis and treatment of thyroid cancer.AI technology has notably enhanced the diagnostic accuracy of thyroid cancer.By optimizing imaging examinations such as ultrasound and CT scans,it can more precisely identify malignant features of thyroid nodules.In fine-needle aspiration biopsy,the integration of AI with genetic testing technologies has improved both the accuracy and efficiency of diagnosis.In terms of treatment,AI assists in intraoperative functional preservation,reducing the risk of surgical trauma.For instance,it can accurately identify the locations of the recurrent laryngeal nerve and parathyroid glands.Additionally,AI is capable of predicting the efficacy of 131I treatment and the risk of complications,thereby guiding postoperative follow-up and management.The core strength of AI technology lies in its powerful data processing and analytical capabilities,enabling it to uncover latent patterns within data and provide a scientific basis for treatment decision-making.Looking ahead,with continuous technological advancements,AI is expected to propel the diagnosis and treatment of thyroid cancer towards greater intelligence and precision.However,challenges such as data privacy and algorithm transparency need to be addressed.This article provides a review of the research progress of AI technology in the fields of diagnosis,treatment,and prognosis prediction of thyroid cancer,explores the current strengths and weaknesses of AI technology,and looks forward to its future development directions while acknowledging challenges like data privacy and algorithm transparency.

Objective:To investigate the effects and possible mechanisms of targeted inhibition of Polo-like kinase 1 (PLK1) on the proliferation, mitosis and apoptosis of cervical cancer cells.Methods:Logarithmically growing human cervical cancer cell lines HeLa and C-33A were selected, and cells treated with 10 and 20 nmol/L PLK1 inhibitor GSK461364 were used as different concentrations of GSK461364 groups, while cells not treated with GSK461364 were used as the control group. CCK-8 method was used to detect cell proliferation ability (represented by absorbance values at wavelength 450 nm), flow cytometry was used to detect chromosome ploidy (propidium iodide staining), mitochondrial membrane potential detected by flow cytometry was used to evaluate cell apoptosis status (JC-1 fluorescent probe, the cells where the JC-1 monomers emitting green fluorescence were located were apoptotic cells), and Western blotting was used to detect the expression levels of cell cycle and apoptosis-related proteins.Results:The results of CCK-8 method showed that the proliferation ability of HeLa cells was lower than that of the control group after 24 hours of treatment with 10 and 20 nmol/L GSK461364 and continued culture for 24, 48 and 72 hours without GSK461364. The proliferation ability of C-33A cells was lower than that of the control group after 24 hours of treatment with 10 and 20 nmol/L GSK461364 and continued culture for 48 and 72 hours without GSK461364, and the differences were statistically significant (all P < 0.05). The results of flow cytometry analysis showed that after 24 hours of treatment with GSK461364 and continued culture for 72 hours without GSK461364, the proportions of polyploid cell subpopulations in HeLa cells of the 10 and 20 nmol/L GSK461364 groups and the control group were (13.89±3.73)%, (12.30±5.49)% and (9.86±1.15)%, respectively, with no statistically significant difference ( F = 0.82, P > 0.05); the proportions of polyploid cell subpopulations in C-33A cells of the 10 and 20 nmol/L GSK461364 groups and the control group were (8.45±2.20)%, (11.06±2.53)% and (5.42±1.36)%, respectively, with statistically significant difference ( F = 5.46, P = 0.045). Among them, the proportion of polyploid cell subpopulations in the 20 nmol/L GSK461364 group was higher than that in the control group, with statistically significant differences ( t = 3.40, P = 0.027). The results of flow cytometry detection of mitochondrial membrane potential showed that after 24 hours of treatment with GSK461364 and continued culture for 72 hours without GSK461364, the proportions of apoptotic cells in HeLa cells of the control group, 10 nmol/L GSK461364 group and 20 nmol/L GSK461364 group were (3.96±2.28)%, (24.38±4.89)%, and (46.24±4.38)%, respectively, and the difference was statistically significant ( F = 83.18, P < 0.000 1), the proportion of apoptotic cells in the 10 and 20 nmol/L GSK461364 groups was higher than that in the control group, and the difference was statistically significant (both P < 0.01), and the proportion of apoptotic cells in the 20 nmol/L group was higher than that in the 10 nmol/L group ( t = 5.76, P = 0.005); the proportions of apoptotic cells in C-33A cells of the control group, 10 nmol/L GSK461364 group and 20 nmol/L GSK461364 group were (1.81±1.59)%, (5.22±1.57)% and (15.87±5.81)%, respectively, with statistically significant differences ( F = 12.49, P = 0.007), and the proportion of apoptotic cells in the 20 nmol/L group was higher than that in the 10 nmol/L group and the control group (both P < 0.05). The results of Western blotting analysis showed that after 24 hours of treatment with GSK461364 and continued culture for 72 hours without GSK461364, the relative expression levels of cleaved Caspase-9 and cleaved polyadenosine diphosphate-ribose polymerase in HeLa and C-33A cells treated with 10 and 20 nmol/L GSK461364 were higher than those in the control group, and the relative expression levels of cdc25c and phosphorylated cdc25c (Ser216) were lower than those in the control group, and the differences were statistically significant (all P < 0.05). Conclusions:Targeted inhibition of PLK1 can inhibit the proliferation activity of cervical cancer cells in vitro, induce cell mitotic cycle arrest, and promote cell apoptosis; these may be achieved by regulating cell cycle and apoptosis-related proteins.

The incidence of thyroid cancer has been increasing,and early diagnosis and treatment are crucial for improving patient prognosis.With the advancement of artificial intelligence(AI)technology,significant progress has been made in its application in the diagnosis and treatment of thyroid cancer.AI technology has notably enhanced the diagnostic accuracy of thyroid cancer.By optimizing imaging examinations such as ultrasound and CT scans,it can more precisely identify malignant features of thyroid nodules.In fine-needle aspiration biopsy,the integration of AI with genetic testing technologies has improved both the accuracy and efficiency of diagnosis.In terms of treatment,AI assists in intraoperative functional preservation,reducing the risk of surgical trauma.For instance,it can accurately identify the locations of the recurrent laryngeal nerve and parathyroid glands.Additionally,AI is capable of predicting the efficacy of 131I treatment and the risk of complications,thereby guiding postoperative follow-up and management.The core strength of AI technology lies in its powerful data processing and analytical capabilities,enabling it to uncover latent patterns within data and provide a scientific basis for treatment decision-making.Looking ahead,with continuous technological advancements,AI is expected to propel the diagnosis and treatment of thyroid cancer towards greater intelligence and precision.However,challenges such as data privacy and algorithm transparency need to be addressed.This article provides a review of the research progress of AI technology in the fields of diagnosis,treatment,and prognosis prediction of thyroid cancer,explores the current strengths and weaknesses of AI technology,and looks forward to its future development directions while acknowledging challenges like data privacy and algorithm transparency.

Objective:To investigate the effects and possible mechanisms of targeted inhibition of Polo-like kinase 1 (PLK1) on the proliferation, mitosis and apoptosis of cervical cancer cells.Methods:Logarithmically growing human cervical cancer cell lines HeLa and C-33A were selected, and cells treated with 10 and 20 nmol/L PLK1 inhibitor GSK461364 were used as different concentrations of GSK461364 groups, while cells not treated with GSK461364 were used as the control group. CCK-8 method was used to detect cell proliferation ability (represented by absorbance values at wavelength 450 nm), flow cytometry was used to detect chromosome ploidy (propidium iodide staining), mitochondrial membrane potential detected by flow cytometry was used to evaluate cell apoptosis status (JC-1 fluorescent probe, the cells where the JC-1 monomers emitting green fluorescence were located were apoptotic cells), and Western blotting was used to detect the expression levels of cell cycle and apoptosis-related proteins.Results:The results of CCK-8 method showed that the proliferation ability of HeLa cells was lower than that of the control group after 24 hours of treatment with 10 and 20 nmol/L GSK461364 and continued culture for 24, 48 and 72 hours without GSK461364. The proliferation ability of C-33A cells was lower than that of the control group after 24 hours of treatment with 10 and 20 nmol/L GSK461364 and continued culture for 48 and 72 hours without GSK461364, and the differences were statistically significant (all P < 0.05). The results of flow cytometry analysis showed that after 24 hours of treatment with GSK461364 and continued culture for 72 hours without GSK461364, the proportions of polyploid cell subpopulations in HeLa cells of the 10 and 20 nmol/L GSK461364 groups and the control group were (13.89±3.73)%, (12.30±5.49)% and (9.86±1.15)%, respectively, with no statistically significant difference ( F = 0.82, P > 0.05); the proportions of polyploid cell subpopulations in C-33A cells of the 10 and 20 nmol/L GSK461364 groups and the control group were (8.45±2.20)%, (11.06±2.53)% and (5.42±1.36)%, respectively, with statistically significant difference ( F = 5.46, P = 0.045). Among them, the proportion of polyploid cell subpopulations in the 20 nmol/L GSK461364 group was higher than that in the control group, with statistically significant differences ( t = 3.40, P = 0.027). The results of flow cytometry detection of mitochondrial membrane potential showed that after 24 hours of treatment with GSK461364 and continued culture for 72 hours without GSK461364, the proportions of apoptotic cells in HeLa cells of the control group, 10 nmol/L GSK461364 group and 20 nmol/L GSK461364 group were (3.96±2.28)%, (24.38±4.89)%, and (46.24±4.38)%, respectively, and the difference was statistically significant ( F = 83.18, P < 0.000 1), the proportion of apoptotic cells in the 10 and 20 nmol/L GSK461364 groups was higher than that in the control group, and the difference was statistically significant (both P < 0.01), and the proportion of apoptotic cells in the 20 nmol/L group was higher than that in the 10 nmol/L group ( t = 5.76, P = 0.005); the proportions of apoptotic cells in C-33A cells of the control group, 10 nmol/L GSK461364 group and 20 nmol/L GSK461364 group were (1.81±1.59)%, (5.22±1.57)% and (15.87±5.81)%, respectively, with statistically significant differences ( F = 12.49, P = 0.007), and the proportion of apoptotic cells in the 20 nmol/L group was higher than that in the 10 nmol/L group and the control group (both P < 0.05). The results of Western blotting analysis showed that after 24 hours of treatment with GSK461364 and continued culture for 72 hours without GSK461364, the relative expression levels of cleaved Caspase-9 and cleaved polyadenosine diphosphate-ribose polymerase in HeLa and C-33A cells treated with 10 and 20 nmol/L GSK461364 were higher than those in the control group, and the relative expression levels of cdc25c and phosphorylated cdc25c (Ser216) were lower than those in the control group, and the differences were statistically significant (all P < 0.05). Conclusions:Targeted inhibition of PLK1 can inhibit the proliferation activity of cervical cancer cells in vitro, induce cell mitotic cycle arrest, and promote cell apoptosis; these may be achieved by regulating cell cycle and apoptosis-related proteins.

Objective:To establish a prediction model of risk factors for early Q-T interval prolongation after acute myocardial infarction (AMI), which helps prevent and reduce the occurrence of acute malignant events.Methods:This is a case-control study. A total of 100 patients with Q-T interval prolongation after AMI who received treatment at Heilongjiang Provincial Hospital from January 2018 to December 2022 were included in this study. An additional 100 patients without Q-T interval prolongation after AMI who concurrently received treatment in the same hospital were also included in this study. Two model groups, including model group 1 (with Q-T interval prolongation, n = 50) and model group 2 (without Q-T interval prolongation, n = 50), and two test groups, including test group 1 (with Q-T interval prolongation, n = 50) and test group 2 (without Q-T interval prolongation, n = 50), were designated. Logistic regression analysis was performed to construct a prediction model of risk factors for Q-T interval prolongation. The area under the receiver operating characteristic curve was determined to evaluate the prediction model. The value of the prediction model was validated in the test groups. Results:Multivariate logistic regression showed that female gender ( OR = 2.307, 95% CI: 0.09-0.91, P = 0.041) and heart failure ( OR = 3.087, 95% CI: 1.15-8.27, P = 0.025) were independent risk factors for early Q-T interval prolongation after AMI. The area under the receiver operating characteristic curve of the prediction model was 0.770, with a sensitivity of 84.0%, a specificity of 66.0%, the Jordan index of 0.44, and the corresponding optimal critical value of 0.43. This indicates good fit of the model. Conclusion:Female gender and heart failure are independent risk factors for early Q-T interval prolongation after AMI. The model constructed based on the above-mentioned risk factors fits well and has a high predictive value, which helps reduce the occurrence of early Q-T interval prolongation after AMI.

Objective:To understand the frailty perception and coping experiences of elderly patients with hip fractures from the patients' perspective, providing insights for healthcare professionals on managing frailty.Methods:A purposive sampling method was used to select 12 elderly patients with hip fractures and frailty who were hospitalized at Tenth People's Hospital of Tongji University from September to October 2023. A phenomenological approach was adopted for this qualitative study, conducting semi-structured interviews to explore the patients' frailty perceptions and coping experiences. NVivo 11.0 software and Colaizzi's seven-step analysis method were used to organize and analyze the interview data.Results:The frailty perceptions of elderly hip fracture patients were categorized into four themes: multidimensional physiological challenges (e.g., aging of the body, nutritional imbalances, pain and sleep disturbances) ; limitations in daily life (e.g., mobility impairments, avoidance of social activities) ; heavy psychological burdens (e.g., uncertainty about the illness, low self-efficacy, feelings of guilt towards the family) ; insufficient social support (e.g., lack of age-friendly environments and limited medical policy coverage). The patients' coping strategies were grouped into two themes: active coping (e.g., self-encouragement, peer support, actively seeking relevant knowledge and guidance) ; passive coping (e.g., neglecting the situation) .Conclusions:Frailty brings multiple negative impacts on the physical, psychological, daily life and social aspects of elderly hip fracture patients; while most patients adopt a positive attitude towards frailty, some exhibit signs of emotional exhaustion and passivity. Medical staff should pay attention to the frailty perceptions of elderly hip fracture patients, identify related symptoms early, provide comprehensive support to alleviate the physical and psychological burden, and encourage patients to face frailty challenges optimistically, adopting proactive measures to slow its progression.

Objective:To extract and summarize the best available evidence on frailty management for elderly patients with hip fractures, providing a reference for developing clinically applicable management protocols.Methods:Following the "6S" evidence model, a systematic search was conducted across national and international databases and guideline websites for evidence on frailty management in elderly hip fracture patients, including guidelines, evidence summaries, systematic reviews, best practices, and expert consensus, with a search period from June 2018 to December 2023. Two researchers independently evaluated the quality of the literature, selecting studies that met inclusion criteria and extracting relevant evidence.Results:A total of 2 589 articles were identified, with 20 articles included: seven guidelines, two best practice standards, one evidence summary, seven expert consensus documents, and three systematic reviews. The best evidence was summarized across six domains: frailty screening, multidisciplinary collaboration, pain management, nutritional management, functional exercise, and discharge guidance, yielding 45 recommendations.Conclusions:The best evidence for frailty management in elderly patients with hip fractures summarized in this study offers valuable insights and scientific guidance for clinical healthcare providers. When applying this evidence, it is recommended to first adapt it to local contexts, considering factors such as institutional environment, healthcare policies, and patient preferences, before conducting implementation research on evidence translation.

Objective:To understand the frailty perception and coping experiences of elderly patients with hip fractures from the patients' perspective, providing insights for healthcare professionals on managing frailty.Methods:A purposive sampling method was used to select 12 elderly patients with hip fractures and frailty who were hospitalized at Tenth People's Hospital of Tongji University from September to October 2023. A phenomenological approach was adopted for this qualitative study, conducting semi-structured interviews to explore the patients' frailty perceptions and coping experiences. NVivo 11.0 software and Colaizzi's seven-step analysis method were used to organize and analyze the interview data.Results:The frailty perceptions of elderly hip fracture patients were categorized into four themes: multidimensional physiological challenges (e.g., aging of the body, nutritional imbalances, pain and sleep disturbances) ; limitations in daily life (e.g., mobility impairments, avoidance of social activities) ; heavy psychological burdens (e.g., uncertainty about the illness, low self-efficacy, feelings of guilt towards the family) ; insufficient social support (e.g., lack of age-friendly environments and limited medical policy coverage). The patients' coping strategies were grouped into two themes: active coping (e.g., self-encouragement, peer support, actively seeking relevant knowledge and guidance) ; passive coping (e.g., neglecting the situation) .Conclusions:Frailty brings multiple negative impacts on the physical, psychological, daily life and social aspects of elderly hip fracture patients; while most patients adopt a positive attitude towards frailty, some exhibit signs of emotional exhaustion and passivity. Medical staff should pay attention to the frailty perceptions of elderly hip fracture patients, identify related symptoms early, provide comprehensive support to alleviate the physical and psychological burden, and encourage patients to face frailty challenges optimistically, adopting proactive measures to slow its progression.

Objective:To extract and summarize the best available evidence on frailty management for elderly patients with hip fractures, providing a reference for developing clinically applicable management protocols.Methods:Following the "6S" evidence model, a systematic search was conducted across national and international databases and guideline websites for evidence on frailty management in elderly hip fracture patients, including guidelines, evidence summaries, systematic reviews, best practices, and expert consensus, with a search period from June 2018 to December 2023. Two researchers independently evaluated the quality of the literature, selecting studies that met inclusion criteria and extracting relevant evidence.Results:A total of 2 589 articles were identified, with 20 articles included: seven guidelines, two best practice standards, one evidence summary, seven expert consensus documents, and three systematic reviews. The best evidence was summarized across six domains: frailty screening, multidisciplinary collaboration, pain management, nutritional management, functional exercise, and discharge guidance, yielding 45 recommendations.Conclusions:The best evidence for frailty management in elderly patients with hip fractures summarized in this study offers valuable insights and scientific guidance for clinical healthcare providers. When applying this evidence, it is recommended to first adapt it to local contexts, considering factors such as institutional environment, healthcare policies, and patient preferences, before conducting implementation research on evidence translation.

Mesh-related visceral complications caused by mesh erosion after tension-free inguinal hernia repair are one kind of rare long-term complications, but they are easily neglected. Interval time from initial hernia repair to mesh-related visceral complications by preperitoneal and laparoscopic repair is short. Rutkow and transabdominal preperitoneal repair have the highest reported rate. Lichtenstein has the longest interval time and the lowest reported rate. The most frequently eroded organs are sigmoid colon, bladder and small intestine. The common clinical manifestations of sigmoid colon erosion are hematochezia, abdominal wall fistula and colitis, hematuria and recurrent urinary tract infection in bladder erosion cases, intestinal obstruction and abdominal wall fistula in intestinal erosion case, sigmoid-bladder fistula and intestinal-bladder fistula in multiple organ erosion cases. Resection or repair of corresponding organs with mesh removal have good efficacies in most patients. The authors summarize and analyze researches on mesh-related visceral complications after tension-free inguinal hernia repair from 1994 to 2021, review their advances, in order to raise awareness of such complications in clinicians.